Taiwan biotechnology, pharmaceutical, medical devices
In the lead up to the Bio Connections Australia 13-14 November, Melbourne conference, we spoke with US-based pharmaceutical firm, Cerebral Therapeutics, who have recently undertaken a proof of concept clinical study in Australia, using a proprietary formulation to treat refractory epilepsy.
Read more
Organised by IBC Asia, the annual Biopharma Development & Production (BDP) Week took place on 16 – 17 May 2018 at Hilton Shanghai Hongqiao Hotel.
Read moreTaipei, Taiwan-based Lumosa Therapeutics Co., Ltd., a company focused on developing treatments for neurological and inflammatory disease, announced recently that it had engaged Cincinnati-headquartered Camargo Pharmaceutical Services for regulatory consulting and strategic development services for LT1001 (Naldebain®, dinalbuphine sebacate IM injection) in the US.
Read moreSingapore-headquartered ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted treatments for Asia prevalent cancer types, recently announced the signing of a research collaboration agreement with Academia Sinica’s Genomic Research Centre, one of Taiwan’s leading research institutions.
Read moreIn Taiwan, biotech is finally booming, and new companies, service providers and manufacturing facilities are emerging to fill rapidly growing industry needs. BioSpectrum Asia recently spoke to Dr. Apo Huang, Secretary General, BioTaiwan on the current growth in the Taiwanese biotech sector.
Read more亞洲生技產業年度盛會–2017台灣生技月(BioTaiwan 2017)活動於6月28日-7月2日於南港舉辦，並於今日(7/2)閉幕。總計今年共有超過600家國內外指標性大廠與1310個攤位參與生技展，吸引超過9萬人次進場參觀，促成近350場的商機媒合。
Read more
